No advantage of a rotational continuation phase in acute lymphoblastic leukemia in childhood treated with a BFM back‐bone therapy
- 10 March 2011
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 57 (1), 47-55
- https://doi.org/10.1002/pbc.23097
Abstract
Background Our aim was to compare two different schedules of maintenance in pediatric acute lymphoblastic leukemia (ALL) treated with a BFM‐based therapy, in a randomized study: an Arm with 6‐MP + MTX (with or without vincristine and dexamethasone pulses) versus a more intensive continuation phase. Procedure From January 1996 to November 2002, 429 eligible children with ALL were enrolled in a protocol with BFM‐based back‐bone, followed by a randomized continuation phase in standard (SRG) and intermediate (IRG) risk groups. Patients were randomized between Arms A and B for SRG and B or C for IRG. Arms A and C consisted of 6‐MP and MTX and in Arm C, six pulses of VCR and dexamethasone were added. Arm B combined four pairs of drugs rotated weekly. All risk‐groups received maintenance until completing 2 years of therapy from diagnosis. Results With a median follow‐up of 138 (range: 96–178) months, the overall pEFS (SE) was 72 (6)% for all patients and the different risk groups showed: SRG: 85 (3)%, IRG: 71 (1)%, and HRG: 42 (7)% (P‐value ≤0.0001). The pDFS (SE) according to the assigned arm of maintenance was, for Arm A: 89 (3)% and for Arm B: 85 (4)% in SRG, and, for Arm B: 77 (4)% and for Arm C: 75 (4)% in IRG, at 10 years follow‐up. There were no statistically significant differences in outcome between arms of maintenance for both risk groups. Conclusions In protocols with initial BFM‐based strategy, a more intensive continuation phase did not benefit any risk group of patients. Pediatr Blood Cancer 2011;57:47–55.Keywords
This publication has 20 references indexed in Scilit:
- Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951Blood, 2010
- Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201Blood, 2007
- Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trialThe Lancet, 2007
- Acute leukemia of dendritic cell lineage in childhood: incidence, biological characteristics and outcomeLeukemia & Lymphoma, 2006
- Treatment results in childhood acute lymphoblastic leukemia with a modified ALL-BFM’90 protocol: lack of improvement in high-risk groupLeukemia Research, 1999
- Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 1998
- Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyThe Lancet, 1991
- Results and Significance of Six Randomized Trials in Four Consecutive ALL-BFM StudiesPublished by Springer Science and Business Media LLC ,1990
- On distribution-free tests for equality of survival distributionsBiometrika, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958